Leerink Partners initiates coverage on Revvity (NYSE:RVTY) with a Outperform rating and announces Price Target of $125.

Barclays analyst Luke Sergott maintains Revvity (NYSE:RVTY) with a Equal-Weight and lowers the price target from $116 to $115.

Baird analyst Catherine Ramsey maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $126 to $127.

During the last three months, 4 analysts shared their evaluations of Revvity (NYSE:RVTY), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 1 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $123.25, along with a high estimate of $130.00 and a low estimate of $110.00. Witnessing a positive shift,

TD Cowen analyst Dan Brennan maintains Revvity (NYSE:RVTY) with a Buy and raises the price target from $123 to $130.

U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc. (NASDAQ:AMZN) on Tuesday and Apple Inc. (NASDAQ:AAPL) on Thursday, a pivotal Federal Reserve Open Market Committee meeting on Wednesday, and the April’s jobs report on Friday. The S&P 500 rose 0.2% by midday trading in New York, following a 1% surge last Friday. Both the tech-heavy Nasdaq 100 and blue-chip stocks in the Dow Jones made similar gains. Small caps, as tracked by iShares Russell 2000 ETF (NYSE:IWM), outperformed large-cap stocks, rising as much as 0.9%. Tesla Inc. (NASDAQ:TSLA) g

Revvity (NYSE:RVTY) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.93 by 5.38 percent. This is a 2.97 percent decrease over earnings of $1.01 per share from the same period last year. The company reported quarterly sales of $649.920 million which beat the analyst consensus estimate of $646.843 million by 0.48 percent. This is a 3.70 percent decrease over sales of $674.865 million the same period last year.

10-Q - REVVITY, INC. (0000031791) (Filer)

8-K - REVVITY, INC. (0000031791) (Filer)

10-Q - REVVITY, INC. (0000031791) (Filer)

8-K - REVVITY, INC. (0000031791) (Filer)

11-K - REVVITY, INC. (0000031791) (Filer)

SD - REVVITY, INC. (0000031791) (Filer)

10-Q - REVVITY, INC. (0000031791) (Filer)

8-K - REVVITY, INC. (0000031791) (Filer)

8-K - REVVITY, INC. (0000031791) (Filer)

ARS - REVVITY, INC. (0000031791) (Filer)

Revenue of $684 million; 2% reported growth; 2% organic growth GAAP EPS of $0.77; Adjusted EPS from continuing operations of $1.28 Raises full year 2024 adjusted EPS guidance Authorizes new $1 billion share repurchase program To host Investor Day on November 21st Revvity, Inc. (NYSE:RVTY), today reported financial results for the third quarter ended September 29, 2024. The Company reported GAAP earnings per share of $0.77, as compared to $0.08 in the same period a year ago. GAAP revenue for the quarter was $684 million, as compared to $671 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $98 million, as compared to $69 m

The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 7, 2025 to all shareholders of record at the close of business on January 17, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, scre

Enables transcription of handwritten test request forms to digitized format Utilizes innovative AI for higher accuracy and efficiency Data is securely processed with ISO27001 compliant solution Revvity, Inc. (NYSE:RVTY) today announced the launch of Revvity Transcribe AI, an innovative optical character recognition (OCR) service designed to convert handwritten text on test request forms into a digitized format. This cutting-edge solution is now available to clinical laboratories, aiming to streamline workflows and reduce manual data entry tasks. Revvity Transcribe AI addresses the need for laboratories to quickly and accurately process test request forms. In many laboratories, this

Revvity, Inc. (NYSE:RVTY) today unveils its annual Impact Report, a declaration of the Company's sustainability, social and governance strategy, initiatives and performance. The report showcases Revvity's continued evolution and strengthened commitments to creating a lasting, positive impact on the world. "Whether it's from developing groundbreaking solutions that drive positive health outcomes or through our sustainability initiatives, such as reducing waste and carbon emissions, we are making substantial strides in creating a healthier, cleaner and more inclusive world for generations to come," said Prahlad Singh, president and chief executive officer at Revvity. "The duly named Impact R

Revvity, Inc. (NYSE:RVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows

Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences in September 2024: 2024 Wells Fargo Healthcare Conference – Boston, MA Wednesday, September 4, 2024 8:45 a.m. ET - Max Krakowiak, senior vice president and chief financial officer 2024 Baird Global Healthcare Conference – New York City, NY Tuesday, September 10, 2024 12:15 p.m. ET - Steve Willoughby, senior vice president, investor relations, ESG, risk Attendees will receive an update on the Company and its strategic priorities. Live audio webcasts will be available on the Events section of the Company's website. Replays of the presentations will be posted on the Revvity Investor Relatio

Revenue of $692 million; (2)% reported growth; (1)% organic growth GAAP EPS of $0.45; Adjusted EPS from continuing operations of $1.22 Raises full year 2024 adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 30, 2024. The Company reported GAAP earnings per share of $0.45, as compared to $0.28 in the same period a year ago. GAAP revenue for the quarter was $692 million, as compared to $709 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $86 million, as compared to $78 million for the same period a year ago. GAAP operating profit margin from continuing opera

The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 8, 2024 to all shareholders of record at the close of business on October 18, 2024. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screenin

Revvity, Inc. (NYSE:RVTY), today announced that it will release its second quarter 2024 financial results prior to market open on Monday, July 29, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflo

Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano's VIA™ software to Revvity's next generation sequencing (NGS) customers as part of its newborn sequencing research workflowVIA is expected to enhance Revvity's newborn sequencing solution by adding an assessment of copy number variation (CNV) to the NGS solution report and streamlining the workflow's interpretation capabilities SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO), today announced that it has entered into a software marketing agreement with Revvity, Inc. (NYSE:RVTY) under which Revvity will market and co